Thozhukat Sathyapalan1, Zeeshan Javed1, Eric S Kilpatrick2, Anne-Marie Coady3, Stephen L Atkin4. 1. Department of Academic Endocrinology, Diabetes and Metabolism, University of Hull, Hull, UK. 2. Sidra Research Centre, Doha, Qatar. 3. Department of Obstetric Ultrasound, Hull & East Yorkshire Women's & Children's Hospital, Hull, UK. 4. Weill Cornell Medicine Qatar, Doha, Qatar.
Abstract
CONTEXT: Animal studies suggest that cannabinoid receptor-1 (CB-1) blockade reduces inflammation and neovascularization by decreasing vascular endothelial growth factor (VEGF) levels associated with a reduction in inflammatory markers, thereby potentially reducing cardiovascular risk. OBJECTIVE: To determine the impact of CB1 antagonism by rimonabant on VEGF and inflammatory markers in obese PCOS women. DESIGN: Randomized, open-labelled parallel study. SETTING:Endocrinology outpatient clinic in a referral centre. SUBJECTS:Twenty patients with PCOS (PCOS) and biochemical hyperandrogenaemia with a body mass index of ≥30 kg/m2 were recruited. Patients were randomized to 1·5 g daily of metformin or 20 mg daily of rimonabant. MAIN OUTCOME MEASURES: Post hoc review to detect VEGF and pro-inflammatory cytokinesTNF-α, IL-1β, IL-1ra, IL-2, IL6, IL-8, IL-10 and MCP-1 before and after 12 weeks of treatment. RESULTS: After 12 weeks of rimonabant treatment, there was a significant increase in VEGF (99·2 ±17·6 vs 116·2 ± 15·8 pg/ml, P < 0·01) and IL-8 (7·4 ± 11·0 vs 18·1 ± 13·2 pg/ml, P < 0·05) but not after metformin (VEGF P = 0·7; IL-8 P = 0·9). There was no significant difference in the pro-inflammatory cytokinesTNF-α, IL-1β, IL-1ra, IL-2, IL6, IL-8, IL-10 and MCP-1 following either treatment. CONCLUSION: This study suggests that rimonabant CB-I blockade paradoxically raised VEGF and the cytokine IL-8 in obese women with PCOS that may have offset the potential benefit associated with weight loss.
RCT Entities:
CONTEXT: Animal studies suggest that cannabinoid receptor-1 (CB-1) blockade reduces inflammation and neovascularization by decreasing vascular endothelial growth factor (VEGF) levels associated with a reduction in inflammatory markers, thereby potentially reducing cardiovascular risk. OBJECTIVE: To determine the impact of CB1 antagonism by rimonabant on VEGF and inflammatory markers in obese PCOSwomen. DESIGN: Randomized, open-labelled parallel study. SETTING: Endocrinology outpatient clinic in a referral centre. SUBJECTS: Twenty patients with PCOS (PCOS) and biochemical hyperandrogenaemia with a body mass index of ≥30 kg/m2 were recruited. Patients were randomized to 1·5 g daily of metformin or 20 mg daily of rimonabant. MAIN OUTCOME MEASURES: Post hoc review to detect VEGF and pro-inflammatory cytokines TNF-α, IL-1β, IL-1ra, IL-2, IL6, IL-8, IL-10 and MCP-1 before and after 12 weeks of treatment. RESULTS: After 12 weeks of rimonabant treatment, there was a significant increase in VEGF (99·2 ± 17·6 vs 116·2 ± 15·8 pg/ml, P < 0·01) and IL-8 (7·4 ± 11·0 vs 18·1 ± 13·2 pg/ml, P < 0·05) but not after metformin (VEGF P = 0·7; IL-8 P = 0·9). There was no significant difference in the pro-inflammatory cytokines TNF-α, IL-1β, IL-1ra, IL-2, IL6, IL-8, IL-10 and MCP-1 following either treatment. CONCLUSION: This study suggests that rimonabantCB-I blockade paradoxically raised VEGF and the cytokine IL-8 in obesewomen with PCOS that may have offset the potential benefit associated with weight loss.
Authors: María de Los Ángeles Nuñez-Lumbreras; José Luis Castañeda-Cabral; María Guadalupe Valle-Dorado; Vicente Sánchez-Valle; Sandra Orozco-Suárez; Rosalinda Guevara-Guzmán; Iris Martínez-Juárez; Mario Alonso-Vanegas; Fruzsina Walter; Maria A Deli; Francia Carmona-Cruz; Luisa Rocha Journal: Front Behav Neurosci Date: 2021-01-20 Impact factor: 3.558
Authors: Lannie O'Keefe; Teresa Vu; Anna C Simcocks; Kayte A Jenkin; Michael L Mathai; Deanne H Hryciw; Dana S Hutchinson; Andrew J McAinch Journal: Int J Mol Sci Date: 2022-09-28 Impact factor: 6.208
Authors: Alexandra E Butler; Vimal Ramachandran; Thomas Keith Cunningham; Rhiannon David; Nigel J Gooderham; Manasi Benurwar; Soha R Dargham; Shahina Hayat; Thozhukat Sathyapalan; S Hani Najafi-Shoushtari; Stephen L Atkin Journal: Front Endocrinol (Lausanne) Date: 2020-09-30 Impact factor: 5.555